Vsk Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 3 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 0.60 M
- Revenue Growth -8.31%
- Profit Growth 32.16%
- Ebitda 192.89%
- Net Worth 0.31%
- Total Assets -21.49%
About Vsk Medicines
Vsk Medicines Private Limited (VMPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 November 2009 and has a history of 15 years and three months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.60 M.
Snehal Kashikar and Vinayak Pralhadrao serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232PN2009PTC134968
- Company No.
134968
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Nov 2009
- Date of AGM
29 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Vsk Medicines?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Snehal Kashikar  | Director | 13-Nov-2009 | Current |
| Vinayak Pralhadrao | Director | 30-Jun-2010 | Current |
Financial Performance of Vsk Medicines.
Vsk Medicines Private Limited, for the financial year ended 2017, experienced Minor drop in revenue, with a 8.31% decrease. The company also saw a substantial improvement in profitability, with a 32.16% increase in profit. The company's net worth moved up by a moderate rise of 0.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vsk Medicines?
In 2017, Vsk Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.60 M
₹0
Charges Breakdown by Lending Institutions
- Small & Medium Enterprises City Centre State Bank Of India : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2010 | Small & Medium Enterprises City Centre State Bank Of India | ₹0.60 M | Open |
How Many Employees Work at Vsk Medicines?
Unlock and access historical data on people associated with Vsk Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vsk Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vsk Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
